WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > BioDiagene
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
PRNewswire | May 22, 2023
Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today its partnership with Alivio Health. This new agreement opens the door to preferred access for Alivio Health clients and providers to the valuable information offered by the CELLSEARCH CTC tests, which allow longitudinal monitoring of cancer patients at any time during the course of the disease. Starting from a simple blood draw, CELLSEARCH CTC tests provide valuable information on a ...
Cell and Gene Therapy
Cellistic and Ncardia | September 20, 2022
Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...
PR.com | January 13, 2020
DECK 7 is proud to present an exciting interview with the Co-Founder & Chief Evangelist at Terminus, Sangram Vajre. He is an author, keynote speaker, 3x CMO, host of the daily #FlipMyFunnel podcast, entrepreneur and category maker. Sangram has been a driving force behind the success of Terminus and building the ABM subcategory of marketing technology. Before co-founding Terminus, Sangram was Head of Marketing at Pardot through its acquisition by ExactTarget and then Salesforce. A contributin...
Medical
Palatin Technologies, Inc | December 29, 2021
Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...
MedTech
Video
Cell and Gene Therapy, Medical
Whitepaper
Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE